None of the estimates for this biotechnology stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Endocyte currently carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Investors interested in the biotechnology space may consider better-ranked stocks such as Alcobra Ltd. (ADHD), Auxilium Pharmaceuticals Inc. (AUXL) and Biodel Inc. (BIOD), each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment